Vaginal Dryness After Menopause: Causes, Treatment & When to See a Doctor

Vaginal dryness affects up to 84% of postmenopausal women, yet research consistently shows that fewer than 1 in 4 ever bring it up with a doctor.¹ It is quietly accepted as an inevitable part of ageing. It is not. It is a treatable, hormone-driven condition with effective options that most women have never been told about.

This guide explains what's happening, what actually works, and when it's worth getting professional support.

What Is Vaginal Dryness After Menopause?

The medical term is Genitourinary Syndrome of Menopause (GSM) — previously called vaginal atrophy or atrophic vaginitis. GSM is the umbrella term for a cluster of symptoms affecting the vagina, vulva, and lower urinary tract that arise when oestrogen levels decline.

GSM is distinct from temporary vaginal dryness caused by dehydration, stress, or inadequate arousal. This is a structural, physiological change — and without treatment, it tends to worsen over time, not improve on its own.

Common symptoms include:

• Vaginal dryness — a persistent dry, raw, or papery sensation
• Burning or stinging, particularly with urination
• Itching or irritation, especially after activity
• Dyspareunia — pain during sexual intercourse
• Vaginal discharge changes — lighter, thinner, or more watery
• Urinary symptoms — increased urgency, frequency, or recurrent urinary tract infections (UTIs)
• Spotting after sex, due to thinning of vaginal walls

Not all women experience all of these. Some have only mild dryness. Others find sex has become acutely painful, or that UTIs have become a near-monthly occurrence.

Why Does Menopause Cause Vaginal Dryness?

The Role of Oestrogen

Oestrogen maintains the health of the vaginal and vulvar tissues by:

• Stimulating collagen production, which keeps tissues thick and elastic
• Supporting the vaginal epithelium (the inner lining), which requires regular cell turnover
• Promoting glycogen production in vaginal cells, which feeds the lactobacillus bacteria that maintain acidic pH
• Driving natural lubrication by stimulating vaginal transudate (fluid secretion through vaginal walls)

When oestrogen declines — whether through natural menopause, surgical menopause (removal of the ovaries), or chemotherapy — all of these processes slow down.

The result: vaginal walls become thinner, drier, and less elastic. The vaginal pH rises from its normal acidic range (~3.8–4.5) to a more alkaline level (~5–7), which disrupts the protective microbiome and increases susceptibility to infection. The tissue becomes more fragile and more easily irritated.²

Why Symptoms Worsen Over Time

Unlike hot flashes, which often improve in the years after menopause, GSM tends to progress without treatment. The longer the tissue is deprived of oestrogen, the more atrophic changes accumulate. This is why some women who were not significantly bothered during early menopause find symptoms more pronounced 5–10 years later.

Regular sexual activity (including solo activity) and pelvic floor exercise can help slow tissue changes by maintaining blood flow, but they do not reverse oestrogen deficiency — only treatment does.

Treatment Options for Vaginal Dryness After Menopause

1. Vaginal Moisturisers (OTC)

Non-hormonal vaginal moisturisers — such as products containing hyaluronic acid, polycarbophil, or sodium hyaluronate — are a recommended first-line option for mild to moderate symptoms.³

Unlike lubricants (which are used at the moment of intercourse), moisturisers are applied regularly (typically every 2–3 days) to maintain baseline tissue hydration. They do not address the underlying hormonal cause, but can significantly reduce dryness and discomfort for many women.

Look for products specifically formulated for vaginal use. Many standard body moisturisers contain fragrances or preservatives that irritate vaginal tissue. Hyaluronic acid-based vaginal gels have shown comparable efficacy to low-dose topical oestrogen in some studies, particularly for dryness and pH normalisation.⁴

2. Lubricants

Water-based or silicone-based lubricants used at the time of intercourse can make sex more comfortable immediately. They are not a standalone treatment for GSM but are an important adjunct — especially when used alongside other therapies.

Avoid lubricants containing glycerine, flavouring, or warming agents, which can disrupt vaginal pH and increase irritation.

3. Local Vaginal Oestrogen

For moderate to severe symptoms, or when OTC options are insufficient, local (vaginal) oestrogen therapy is the most effective and best-evidenced treatment.

Formulations include:

• Vaginal cream (applied with an applicator)
• Vaginal tablets or pessaries (inserted vaginally 2–3 times per week)
• Vaginal ring (inserted by a clinician, releases oestrogen continuously for 90 days)

Local oestrogen acts directly on vaginal and vulvar tissue. Because the dose is very low and absorbed primarily locally, systemic absorption is minimal — meaning it has a different safety profile from systemic HRT.⁵

The 2022 NAMS (North American Menopause Society) position statement confirms that low-dose vaginal oestrogen is safe for long-term use in most women, including those with a history of breast cancer in certain circumstances — though this should always be discussed with a clinician.⁶

Typical results: improvements in dryness, pH normalisation, reduced UTI frequency, and reduced dyspareunia within 4–12 weeks. Full tissue restoration may take 3–6 months.

4. Systemic HRT

Women already on systemic hormone replacement therapy (oestrogen ± progesterone taken orally, transdermally, or via gel) may still develop GSM — especially on lower systemic doses. In these cases, adding local vaginal oestrogen is often appropriate and does not significantly increase systemic oestrogen load.

For women not on HRT, systemic oestrogen will also address GSM while simultaneously treating hot flashes, sleep disruption, and other menopausal symptoms. A clinician can help determine whether systemic or local therapy (or both) is most appropriate.

5. Ospemifene

Ospemifene is an oral SERM (selective oestrogen receptor modulator) approved for dyspareunia and vaginal dryness due to menopause in women who cannot or prefer not to use vaginal products. It acts as an oestrogen agonist on vaginal tissue without stimulating the uterine lining.⁷

6. Pelvic Floor Physiotherapy

Pelvic floor physiotherapy can be a valuable complement to hormonal or moisturiser-based treatment — particularly where dyspareunia involves pelvic floor tension or vaginismus alongside GSM. A pelvic floor physiotherapist can assess and treat the muscular component of pain during sex.

When to See a Doctor

Vaginal dryness is worth discussing with a doctor when:

• OTC moisturisers are not providing enough relief after 4–6 weeks of consistent use
• Sex has become painful (dyspareunia should always be assessed — it has multiple potential causes)
• You are getting recurrent UTIs (2 or more per year) — this may indicate GSM-related pH disruption
• You have vaginal bleeding after menopause — always warrants investigation to rule out other causes
• Symptoms are significantly affecting your quality of life, relationships, or mental health
• You want to explore prescription options like vaginal oestrogen or ospemifene

Many women hesitate to raise vaginal symptoms with a doctor out of embarrassment. It helps to know that gynaecologists and women's health clinicians ask about these symptoms routinely — and have effective, evidence-based treatments ready.

FAQs

Is vaginal dryness after menopause permanent? Without treatment, GSM tends to worsen over time. With appropriate treatment — particularly local oestrogen — significant improvement is achievable at any stage. Starting treatment earlier typically produces faster results.

Can local oestrogen cause cancer? Low-dose vaginal oestrogen has not been shown to increase breast or endometrial cancer risk in postmenopausal women. However, all hormonal treatments should be discussed with a clinician who knows your individual history.⁶

Do I need to use vaginal oestrogen forever? Symptoms typically return if treatment is stopped, because the underlying oestrogen deficiency remains. Many women use local oestrogen long-term — similar to any ongoing maintenance treatment for a chronic condition.

Can I use coconut oil as a lubricant? Coconut oil is a popular home remedy but is not evidence-based for GSM, can disrupt vaginal pH, and is not compatible with latex condoms. Purpose-formulated vaginal moisturisers and lubricants are preferable.

Get Support for Vaginal Dryness in Singapore

Zoey is a women's health telehealth platform in Singapore offering online consultations with licensed clinicians for menopause symptoms, including vaginal dryness. No in-person appointment required.

→ Book a consultation at zoey.sg

References

1. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2012;67(3):233–238.
2. Gandhi J, Chen A, Freed M, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–711.
3. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068.
4. Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women. J Clin Diagn Res. 2016;10(9):QC01–QC05.
5. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.
6. NAMS. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
7. Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–427.